Addendum
Sotatercept (pulmonary arterial hypertension, WHO functional class IV) – Addendum to Commission A26-12
Report documents
-
Addendum
Sotatercept (pulmonary arterial hypertension, WHO functional class IV) – Addendum to Commission A26-12
Dossier assessment
Indication:
Adults with WHO functional class IV pulmonary arterial hypertension
Result of dossier assessment:
After addendum now: hint of a non-quantifiable added benefit
Additional information
Federal Joint Committee (G-BA)
06-08-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-75
- Commission
- Commission awarded on 23.06.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
- https://doi.org/10.60584/A26-75_V1.1
Connected Projects
-
Dossier assessment
Sotatercept (pulmonary arterial hypertension, WHO functional class IV) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed